Generic Name and Formulations:
Sulfur hexafluoride lipid-type A microspheres (25mg of lipid-type A lyophilized pwd with 60.7mg of sulfur hexafluoride gas); per vial; for IV or intravesical inj after reconstitution.
Indications for LUMASON:
For use in adult patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. For use in ultrasonography of the liver to characterize focal liver lesions in adult and pediatric patients. For use in ultrasonography of the urinary tract for evaluation of suspected or known vesicoureteral reflux in pediatric patients.
See full labeling. Echocardiography: 2mL via IV bolus inj. Ultrasonography of the liver: 2.4mL via IV inj. Both: may repeat dose once if needed. Follow each inj with 5mL normal saline flush.
See full labeling. Ultrasonography of the liver: 0.03mL/kg via IV inj; max 2.4mL per inj. May repeat dose once if needed. Follow each inj with 5mL normal saline flush. Ultrasonography of the urinary tract: 1mL via intravesical bolus inj through the urinary catheter. The bladder may be refilled with normal saline for second cycle of voiding and imaging, without the need of a second Lumason inj.
Do not administer by intra-arterial inj. Risk of cardiopulmonary reactions (may be fatal); increased risk in those with unstable conditions (eg, acute MI, coronary artery syndromes, CHF, ventricular arrhythmias). Have resuscitation equipment and trained personnel readily available. Assess patients with cardiac shunts for embolic phenomena post inj. Monitor for hypersensitivity reactions. Not recommended for use at mechanical indices >0.8; high index values may lead to ventricular arrhythmias. Pregnancy, nursing mothers: no data.
Headache, nausea, dysgeusia, inj site pain, feeling hot; cardiopulmonary reactions, hypersensitivity reactions.
Kit—1 (one vial + diluent + mini-spike)
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Presence of Iris Pigmented Lesions Indicates Melanoma Risk
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT
- Prognostic Significance of Epidermal Growth Factor Receptor Expression in Glioma Patients
- Fathers Can Pass Inherited Ovarian Cancer Risk to Daughters
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|